{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:59:42Z","timestamp":1790240382391,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In resource-limited rural settings, patients with multifocal motor neuropathy (MMN) often present late due to limited access to neurophysiology services, by which time significant axonal damage may have occurred, rendering them less responsive to immunotherapy\u2014yet this clinically subgroup is consistently underrepresented in randomized controlled trials. In this study, we aimed to examined the impact of intravenous immunoglobulin (IVIg) frequency on electrophysiological changes in such undertreated MMN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted across three rural medical centers. Patients receiving\u2009&gt;\u20092 IVIg cycles annually were classified as group A, others as group B. Nerve conduction was assessed at baseline, after the first treatment course, and at the final follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:bold>Results<\/jats:bold>\n                    <\/jats:title>\n                    <jats:p>\n                      Thirty-nine MMN patients initially identified, 11 patients with confirmed conduction block (CB) were included. 27 nerves exhibited definite CB, with 7 (25.9%) in the median nerve, 8 (29.6%) in the ulnar nerve, and 6 (18.5%) in both the tibial and peroneal nerves. The treatment intervals was 4.9\u2009\u00b1\u20091.8 (range, 2.6 to 8.0) months, The follow-up period was 17.2\u2009\u00b1\u20093.3 months (range, 12.0 to 21.0). 7 (63.6%) were in group A, while 4 patients (36.4%) were in group B. There was a clear improvement in mRS scores at the last follow-up compared to baseline (z = -2.795,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). We compared the variations in distal compound muscle action potential (CMAP) amplitude at baseline and the last follow-up, after adjusting for baseline CMAP amplitude, it showed significantly greater improvements in distal CMAP amplitude in group A versus group B (F\u2009=\u200940.217, P\u2009&lt;\u20090.001; B\u2009=\u20092.881, 95% CI 1.941\u2009~\u20093.821,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), with the model accounting for 71.5% of the variance (adjusted R\u00b2= 0.715). The number of CBs decreased from 17 to 14 in group A, with no change in group B (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:bold>Conclusions<\/jats:bold>\n                    <\/jats:title>\n                    <jats:p>High frequency IVIg treatment may be associated with improved CMAP amplitude and mRS in undertreated MMN patients, suggesting potential benefits that require further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05157-0","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:14:38Z","timestamp":1783682078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous immunoglobulin frequency in multifocal motor neuropathy: a retrospective study of nerve conduction outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"Lili","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yake","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"5","key":"5157_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(05)70074-0","volume":"4","author":"JT Van Asseldonk","year":"2005","unstructured":"Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4(5):309\u201319. https:\/\/doi.org\/10.1016\/S1474-4422(05)70074-0.","journal-title":"Lancet Neurol"},{"issue":"4","key":"5157_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","unstructured":"Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2013first revision. J Peripher Nerv Syst. 2010;15(4):295\u2013301. https:\/\/doi.org\/10.1111\/j.1529-8027.2010.00290.x.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"5157_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","volume":"91","author":"WZ Yeh","year":"2020","unstructured":"Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140\u20138. https:\/\/doi.org\/10.1136\/jnnp-2019-321532.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"5157_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","volume":"75","author":"EA Cats","year":"2010","unstructured":"Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75(9):818\u201325. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f0738e.","journal-title":"Neurology"},{"issue":"1","key":"5157_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12974-024-03090-y","volume":"21","author":"K Budding","year":"2024","unstructured":"Budding K, Bos JW, Dijkxhoorn K, et al. IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset. J Neuroinflammation. 2024;21(1):100. https:\/\/doi.org\/10.1186\/s12974-024-03090-y.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"5157_CR6","doi-asserted-by":"publisher","first-page":"e16248","DOI":"10.1111\/ene.16248","volume":"31","author":"PE Doneddu","year":"2024","unstructured":"Doneddu PE, Gentile L, Cocito D, et al. Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database. Eur J Neurol. 2024;31(5):e16248. https:\/\/doi.org\/10.1111\/ene.16248.","journal-title":"Eur J Neurol"},{"issue":"1","key":"5157_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mus.10317","volume":"27","author":"RK Olney","year":"2003","unstructured":"Olney RK, Lewis RA, Putnam TD, et al. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003;27(1):117\u201321. https:\/\/doi.org\/10.1002\/mus.10317.","journal-title":"Muscle Nerve"},{"key":"5157_CR8","doi-asserted-by":"publisher","first-page":"117495","DOI":"10.1016\/j.jns.2021.117495","volume":"427","author":"A Al-Zuhairy","year":"2021","unstructured":"Al-Zuhairy A, Sindrup SH, Jakobsen J. Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy. J Neurol Sci. 2021;427:117495. https:\/\/doi.org\/10.1016\/j.jns.2021.117495.","journal-title":"J Neurol Sci"},{"issue":"7","key":"5157_CR9","doi-asserted-by":"publisher","first-page":"e16305","DOI":"10.1111\/ene.16305","volume":"31","author":"A Al-Zuhairy","year":"2024","unstructured":"Al-Zuhairy A, Jakobsen J, Krarup C. Prevention of axonal loss after immediate dosage titration of immunoglobulin in multifocal motor neuropathy. Eur J Neurol. 2024;31(7):e16305. https:\/\/doi.org\/10.1111\/ene.16305.","journal-title":"Eur J Neurol"},{"issue":"1","key":"5157_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mayocpiqo.2023.12.002","volume":"8","author":"JA Allen","year":"2024","unstructured":"Allen JA, Clarke AE, Harbo T. A Practical Guide to Identify Patients With Multifocal Motor Neuropathy, a Treatable Immune-Mediated Neuropathy. Mayo Clin Proc Innov Qual Outcomes. 2024;8(1):74\u201381. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2023.12.002.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"1","key":"5157_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","volume":"8","author":"L Vlam","year":"2011","unstructured":"Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48\u201358. https:\/\/doi.org\/10.1038\/nrneurol.2011.175.","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 1","key":"5157_CR12","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1007\/s10875-010-9408-3","volume":"30","author":"WL van der Pol","year":"2010","unstructured":"van der Pol WL, Cats EA, van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J Clin Immunol. 2010;30(Suppl 1):S79\u201383. https:\/\/doi.org\/10.1007\/s10875-010-9408-3.","journal-title":"J Clin Immunol"},{"issue":"4","key":"5157_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s00415-009-0130-0","volume":"256","author":"A Baumann","year":"2009","unstructured":"Baumann A, Hess CW, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol. 2009;256(4):608\u201314. https:\/\/doi.org\/10.1007\/s00415-009-0130-0.","journal-title":"J Neurol"},{"issue":"8","key":"5157_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","volume":"77","author":"RC Graham","year":"2006","unstructured":"Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973\u20136. https:\/\/doi.org\/10.1136\/jnnp.2005.081547.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"5157_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.str.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604\u20137. https:\/\/doi.org\/10.1161\/01.str.19.5.604.","journal-title":"Stroke"},{"issue":"6","key":"5157_CR16","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s11136-016-1469-1","volume":"26","author":"MGE Verdam","year":"2017","unstructured":"Verdam MGE, Oort FJ, Sprangers MAG. Item bias detection in the Hospital Anxiety and Depression Scale using structural equation modeling: comparison with other item bias detection methods. Qual Life Res. 2017;26(6):1439\u201350. https:\/\/doi.org\/10.1007\/s11136-016-1469-1.","journal-title":"Qual Life Res"},{"issue":"6","key":"5157_CR17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/(sici)1097-4598(200006)23:6<900::aid-mus9>3.0.co;2-y","volume":"23","author":"BV Taylor","year":"2000","unstructured":"Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve. 2000;23(6):900\u20138. https:\/\/doi.org\/10.1002\/(sici)1097-4598(200006)23:6%26lt;900::aid-mus9%26gt;3.0.co;2-y.","journal-title":"Muscle Nerve"},{"issue":"7","key":"5157_CR18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","volume":"85","author":"E Nobile-Orazio","year":"2014","unstructured":"Nobile-Orazio E, Giannotta C, Musset L, et al. Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy[J]. J Neurol Neurosurg Psychiatry. 2014;85(7):754\u20138. https:\/\/doi.org\/10.1136\/jnnp-2013-305755.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"5157_CR19","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/WNL.45.8.1570","volume":"45","author":"IN Van Schaik","year":"1995","unstructured":"Van Schaik IN, Bossuyt PMM, Brand A, et al. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurol. 1995;45(8):1570\u20137. https:\/\/doi.org\/10.1212\/WNL.45.8.1570.","journal-title":"Neurol"},{"issue":"5","key":"5157_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/jnnp-2014-308118","volume":"86","author":"EA Cats","year":"2015","unstructured":"Cats EA, Van der Pol WL, Tio-Gillen AP, et al. Clonality of anti-GM1 IgM antibodies in multifocal motor neuropathy and the Guillain-Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry. 2015;86(5):502\u20134. https:\/\/doi.org\/10.1136\/jnnp-2014-308118.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"5157_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1212\/01.wnl.0000140497.85952.fa","volume":"63","author":"S Vucic","year":"2004","unstructured":"Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63(7):1264\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000140497.85952.fa.","journal-title":"Neurology"},{"issue":"3","key":"5157_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/mus.27469","volume":"65","author":"DJL Stikvoort Garc\u00eda","year":"2022","unstructured":"Stikvoort Garc\u00eda DJL, Kovalchuk MO, Goedee HS, et al. Motor unit integrity in multifocal motor neuropathy: A systematic evaluation with CMAP scans. Muscle Nerve. 2022;65(3):317\u201325. https:\/\/doi.org\/10.1002\/mus.27469.","journal-title":"Muscle Nerve"},{"key":"5157_CR23","doi-asserted-by":"publisher","first-page":"1478419","DOI":"10.3389\/fneur.2024.1478419","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Roepcke S, Franke R, Yel L. Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy. Front Neurol. 2024;15:1478419. https:\/\/doi.org\/10.3389\/fneur.2024.1478419.","journal-title":"Front Neurol"},{"key":"5157_CR24","doi-asserted-by":"publisher","unstructured":"Doneddu PE, Gallo C, Falzone Y, et al. Nerve conduction abnormalities beyond conduction block in multifocal motor neuropathy. Impact on diagnostic criteria accuracy. Eur J Neurol. 2025;32(9):e70300. https:\/\/doi.org\/10.1111\/ene.70300.","DOI":"10.1111\/ene.70300"},{"key":"5157_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.047688","author":"Ghosh","year":"2005","unstructured":"Ghosh A, Busby M, Kennett R, et al. A practical definition of conduction block in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2005;76(9):1264-8. https:\/\/doi.org\/10.1136\/jnnp.2004.047688","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"5157_CR26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/jnnp.2004.050252","volume":"76","author":"A Ghosh","year":"2005","unstructured":"Ghosh A, Virgincar A, Kennett R, et al. The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2005;76(9):1269\u201372. https:\/\/doi.org\/10.1136\/jnnp.2004.050252.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5157_CR27","doi-asserted-by":"publisher","unstructured":"Van Asseldonk JT , Van den Berg LH ,Van den Berg-Vos RM, et al. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain. 2003;(1):186\u201398. https:\/\/doi.org\/10.1093\/brain\/awg019.","DOI":"10.1093\/brain\/awg019"},{"issue":"3","key":"5157_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jns.12141","volume":"20","author":"EK Vanhoutte","year":"2015","unstructured":"Vanhoutte EK, Faber CG, Van Nes SI, et al. Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS). J Peripheral Nerv Syst. 2015;20(3):296\u2013305. https:\/\/doi.org\/10.1111\/jns.12141.","journal-title":"J Peripheral Nerv Syst"},{"key":"5157_CR29","doi-asserted-by":"publisher","unstructured":"Baldini V, Varallo G, Nuredini A, et al. The psychological burden of neuromuscular Diseases: a narrative review of anxiety, depression, coping, and quality of life. Muscles. 2025;4(4). https:\/\/doi.org\/10.3390\/muscles4040059.","DOI":"10.3390\/muscles4040059"},{"key":"5157_CR30","doi-asserted-by":"publisher","first-page":"1824742","DOI":"10.3389\/fnhum.2026.1824742","volume":"20","author":"I Basta","year":"2026","unstructured":"Basta I, Jeremi\u0107 M, Palibrk A, et al. Long-term motor stability but increasing non-motor burden in multifocal motor neuropathy: a 6-year real-world follow-up study during the COVID-19 era. Front Hum Neurosci. 2026;20:1824742. https:\/\/doi.org\/10.3389\/fnhum.2026.1824742.","journal-title":"Front Hum Neurosci"},{"key":"5157_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2019.02.029","volume":"399","author":"I Bozovic","year":"2019","unstructured":"Bozovic I, Peric S, Basta I, et al. Quality of life in patients with multifocal motor neuropathy from Serbia. J Neurol Sci. 2019;399:151\u20134. https:\/\/doi.org\/10.1016\/j.jns.2019.02.029.","journal-title":"J Neurol Sci"},{"key":"5157_CR32","doi-asserted-by":"publisher","unstructured":"Van den Berg-Vos RM, Franssen H, Wokke JHJ, et al. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain J Neurol. 2002;125(8):1875\u201386. https:\/\/doi.org\/10.1093\/brain\/awf193.","DOI":"10.1093\/brain\/awf193"},{"issue":"1","key":"5157_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clinph.2006.09.020","volume":"118","author":"S Vucic","year":"2007","unstructured":"Vucic S, Black K, Chong PST, et al. Multifocal motor neuropathy with conduction block: Distribution of demyelination and axonal degeneration. Clin Neurophysiol. 2007;118(1):124\u201330. https:\/\/doi.org\/10.1016\/j.clinph.2006.09.020.","journal-title":"Clin Neurophysiol"},{"key":"5157_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2016.11.012","author":"P Manon","year":"2017","unstructured":"Philibert M, Grapperon A M, Delmont E, et al. Monitoring the short-term effect of intravenous immunoglobulins in multifocal motor neuropathy using motor unit number index. Clin Neurophysiol. 2017;128(1):235\u201340. https:\/\/doi.org\/10.1016\/j.clinph.2016.11.012.","journal-title":"Clin Neurophysiol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05157-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05157-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05157-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:04:47Z","timestamp":1790237087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05157-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5157"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05157-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Hangzhou Hospital of Traditional Chinese Medicine. Informed consent was waived because this was a retrospective analysis of routinely collected clinical data, and all patient identifiers were removed prior to analysis, posing no more than minimal risk to participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any identifying images, personal details, or clinical data of participants that would compromise anonymity.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"608"}}